retinoic acid early transcript 1EGenealiases: LETAL · N2DL-4 · NKG2DL4 · RAET1E2 · RL-4 · ULBP4
Q-omics provides the consensus-scored RAET1E profile across patient tissues and cancer cell-line models. RAET1E expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAET1E is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, RAET1E RNA expression shows 15,543 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KIRP, and ACC as cancer lineages where RAET1E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAET1E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAET1E survival associations across molecular data types. RAET1E RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAET1E RNA expression–survival associations across cancer types. High RAET1E expression shows unfavorable associations in KIRP, KICH and ACC, but favorable associations in KIRC, COAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAET1E RNA expression.
This table summarizes RAET1E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RAET1E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAET1E shows lower tumor expression in KIRP, HNSC, KIRC and KICH and higher tumor expression in THCA and LUAD. The KIRP box plot shows higher RAET1E RNA expression in normal versus tumor tissue (log2 FC = −1.508, t-test p < 0.001).
This table shows molecular features associated with RAET1E in patient tissues and cancer cell lines. In patient samples, RAET1E shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAET1E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
